Swiss National Bank
FDMT icon

Swiss National Bank’s 4D Molecular Therapeutics FDMT Stock Holding History

Swiss National Bank’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,500
Closed -$281K – 2415
2024
Q4 		$281K Hold
50,500
– – ﹤0.01% 2434
2024
Q3 		$546K Sell
50,500
-4,900
-9% -$81.3K ﹤0.01% 2419
2024
Q2 		$1.16M Buy
55,400
+1,500
+3% +$37.6K ﹤0.01% 2104
2024
Q1 		$1.72M Buy
53,900
+12,400
+30% +$316K ﹤0.01% 1922
2023
Q4 		$841K Sell
41,500
-4,600
-10% -$60.5K ﹤0.01% 2335
2023
Q3 		$587K Sell
46,100
-15,500
-25% -$259K ﹤0.01% 2470
2023
Q2 		$1.11M Buy
61,600
+23,100
+60% +$425K ﹤0.01% 2232
2023
Q1 		$662K Buy
+38,500
New +$749K ﹤0.01% 2454
2022
Q4 		– Sell
-64,600
Closed -$519K – 2690
2022
Q3 		$519K Hold
64,600
– – ﹤0.01% 2553
2022
Q2 		$451K Buy
64,600
+7,600
+13% +$73.9K ﹤0.01% 2638
2022
Q1 		$862K Buy
57,000
+3,700
+7% +$58.1K ﹤0.01% 2463
2021
Q4 		$1.17M Buy
53,300
+23,700
+80% +$581K ﹤0.01% 2386
2021
Q3 		$798K Buy
29,600
+9,000
+44% +$257K ﹤0.01% 2492
2021
Q2 		$496K Buy
+20,600
New +$631K ﹤0.01% 2623

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Swiss National Bank's FDMT Position: Q1 2025 in Review

Swiss National Bank sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 50,500 shares — an estimated $281K sold.

Swiss National Bank first reported a position in FDMT in Q2 2021 and held it in 14 quarters. The position peaked at $1.72M in Q1 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Swiss National Bank reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 50,500 4D Molecular Therapeutics shares in Q1 2025, an estimated $281K.
  • Swiss National Bank first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 14 quarters.
  • Swiss National Bank's 4D Molecular Therapeutics position peaked at $1.72M in Q1 2024.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.